Featured Press Release
-
2/19/20 4:30 pm ESTWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 fourth quarter and full year financial results on Monday, March 2, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Monday, March 2, 2020 Time 8:30 a.m. EST Toll free (U.S.) 877-876-9173 InternationalSee More
-
2/10/20 9:54 am EST
-- Eagle has exclusive rights to commercialize product for four months beginning February 1, 2022 --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has received final approval from the U.S. Food and Drug Administration (“FDA”) for its novel product, PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®. “We are pleased to receive final approval from FDA and look forward to making PEMFEXY available to the patients who can benefit. Our initial market exclusivity for PEMFEXY represents aSee More -
1/13/20 6:50 am ESTWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Eagle and the University of Pennsylvania (“Penn”) have agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease, including an agreement to fund additional research and provisions regarding commercialization of products developed under the license. “Our collaborationSee More
Upcoming Events & Presentations
-
3/2/20 8:30 am - 9:30 am EST